The SHIELD project aims to transform the early detection of pancreatic cancer, focusing on individuals at high genetic or familial risk. Since pancreatic cancer is often diagnosed at a late stage, early detection can dramatically improve survival and treatment outcomes.

SHIELD validates an innovative blood-based test for the early detection of pancreatic ductal adenocarcinoma (PDAC) and pilots early detection programmes in several European countries. The project will also identify new protein biomarkers for other high-risk conditions and work closely with national screening authorities and patient organisations to support integration into existing screening programmes. By improving early diagnosis across Europe, SHIELD seeks to significantly increase survival rates and change the future of pancreatic cancer care.

The primary objective:

• To validate a novel, blood-based protein diagnostic test for the early detection of pancreatic cancer in individuals with heritable genetic risk and pilot a comprehensive surveillance program.
• SHIELD envisions transforming pancreatic cancer diagnostics by increasing the 5-year survival rate to 30% by 2035 in Europe.

Why it matters:

• Individuals and families with heritable genetic risk will benefit from evidence-based, tailored, affordable, and accessible early detection.
• Policymakers and authorities in Member States and Associated Countries will implement early detection and treatment programmes, supported by appropriate policies and legislation.

Long-term impact:

• Improve the quality of life of cancer patients, survivors, and their families by analysing all key factors and needs related to quality of life.
• Enhance cross-policy cancer prevention strategies.
• Optimise cancer diagnostics and treatment based on equitable access.
• Improve understanding of cancer development in the context of environment, work, and lifestyle.
• Accelerate the digital transformation of research, innovation, and health systems.